Harry Ridgway, Graham J Moore, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, Weronika Hoffmann, Katarzyna Węgrzyn, Niki Vassilaki, George Mpekoulis, Marios Zouridakis, Petros Giastas, Veroniki P Vidali, Konstantinos Kelaidonis, Minos-Timotheos Matsoukas, Marios Dimitriou, Thomas Mavromoustakos, Sotirios Tsiodras, Vasilis G Gorgoulis, Ioannis Karakasiliotis, Christos T Chasapis, John M Matsoukas
BACKGROUND: Pre-existing hypertensive pathologies are linked to worsened outcomes in patients infected with severe-acute respiratory syndrome (SARS-CoV-2). Sartans, a family of anti-hypertensive angiotensin receptor blockers (ARBs), reduce morbidity and mortality in coronavirus 2019 patients by aeffecting angiotensin-converting enzyme-2 (ACE2). The purpose of this study was to determine the anti-SARS-CoV-2viral and antihypertensive abilities of nirmatrelvir, and commercially available (e...
June 3, 2024: Expert Opinion on Therapeutic Targets